Opendata, web and dolomites

ABOPEN

FIRST INSTANT, OFF-THE-LAB AND USER-FRIENDLY BLOOD GROUPING TEST

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ABOPEN project word cloud

Explore the words cloud of the ABOPEN project. It provides you a very rough idea of what is the project "ABOPEN" about.

eldoncards    military    lab    newborn    keeping    women    trained    220    instant    worldwide    tests    moving    format    blood    eradicated    red    millions    personal    majority    2002    pioneering    erase    abopen    kills    distributors    works    world    obstretics    single    stop    deaths    tested    sold    disease    urgent    limitations    accidents    regions    months    federation    founding    sizeable    created    million    babies    prevented    fetus    generate    off    despite    cells    jobs    hospitals    screening    electricity    outside    attacks    141       mothers    precision    company    roi    performed    15    procedure    similarly    rhesus    stored    hdnf    44    gynecology    network    overcoming    pregnant    customers    dry    influential    hdfn    hemolytic    international    37c    minute    immune    profitable    risk    laboratory    affordability    24    easily    pregnancy    rhd    biologicals    turnover    market    setting    eldon    2025    figo    countries    grouping    mother    device    danish    curhe    transfusions    accuracy    children   

Project "ABOPEN" data sheet

The following table provides information about the project.

Coordinator
ELDON BIOLOGICALS A/S 

Organization address
address: SANDTOFTEN 10
city: GENTOFTE
postcode: 2820
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.eldoncard.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELDON BIOLOGICALS A/S DK (GENTOFTE) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15% of RhD(-) women are at risk, 220 million women in developing countries should be tested, since the majority do not know their RhD factor type. At Eldon Biologicals AS (a Danish company created in 2002), we are a profitable company that has already sold millions of EldonCards (a pioneering off-the-lab dry format grouping test) in more than 44 countries and has built a well-established worldwide network of customers and distributors. We are part of the influential International Federation of Gynecology and Obstretics (FIGO) and founding member of CURhE, an international initiative to stop HDNF. Now, we are moving one step further from EldonCards overcoming its limitations to erase HDNF from developing countries. To do so, we have created ABOPEN, a user-friendly off-the-lab grouping test that can be stored for up to 24 months at 37C and works similarly to pregnancy tests, identifying the RhD factor type in just 1 minute and a single-step procedure. ABOPEN can be performed outside a laboratory setting (does not need electricity) by non-trained personnel, while keeping its affordability (it costs just €4), precision and accuracy. ABOPEN has also a sizeable market in developed countries, as an instant and easy to use device to find out about blood grouping for urgent transfusions (accidents, hospitals, military) or just personal information. By end of 2025, we expect to generate €8 million in turnover (ROI of 2.2), while creating 7 new jobs for the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABOPEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABOPEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More